# Doer Biologis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/doer-biologis

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.doerbio.com
- Latest round: Series A (Nov 3, 2020)
- Investors on record: 4

## About

Based in Hangzhou, China and established in 2014, Doer Biologis is a biopharmaceutical company providing bio-macromolecule drugs. The company raised tens of millions of series A funding in 2019, and hundred of millions of series A+ funding in 2020. In 2021, The company was acquired by Pilot Gene Technologies (Hangzhou) Co., Ltd for RMB 490 million. Investor Pilot Gene Technologies (Hangzhou) Co., Ltd became the largest shareholder of Doer Biologis.

The company owns Xlongylation, a platform for the long-term modification of recombinant PEG-like modified (RPEG) proteins, MultipleBody, a multi-target technology platform, and HTS-VHHBody, a platform for the high-throughput discovery and modification of single-domain antibodies. And Accubody ®-- Tumor Precision Therapy Technology Platform and other innovative protein engineering platform technologies. Based on the technology, the company provides antibody drugs and multi-specific protein drugs for oncology, metabolism, ophthalmology.

## Funding rounds

- Series A, Nov 3, 2020 — Sinowisdom, Kaitai Capital, HY Energy Group, Hangzhou Bairui
- Series A, Feb 13, 2019 — Kaitai Capital, Hangzhou Bairui

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Hangzhou Bairui — Series A
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series A
- HY Energy Group — Series A